Clinical Cardiology 907 - Clinical Cardiology Alert - Jul 01, 2005

Target Audience:

This activity is intended for the cardiologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editor
Michael H. Crawford, MD
Professor of Medicine
Chief of Clinical Cardiology
University of California
San Francisco

Editorial Board Members
John P. DiMarco, MD, PhD
Professor of Medicine
Division of Cardiology
University of Virginia
Charlottesville

Jonathan Abrams, MD
Professor of Medicine
Division of Cardiology
University of New Mexico
Albuquerque

Subjects:

  • Four-Year Invasive Follow-Up of Drug-Eluting Stents
  • Severe Tricuspid Regurgitation Post Device Placement
  • Ablation vs Antiarrhythmic for Symptomatic Atrial Fibrillation
  • Heart Rate Profile During Exercise as a Predictor of Sudden Death
  • The Gender Specific Impact of Diabetes and Myocardial Infarction at Baseline and During Follow-Up on Mortality From All Causes and Coronary Heart Disease
  • BNP in Mitral Regurgitation

Objectives:

  • Present the latest information regarding diagnosis and treatment of cardiac disease, including new drug therapies, surgery, and other interventions
  • Discuss the pros and cons of these interventions, as well as possible complications
  • Discuss the pros and cons and cost-effectiveness of new and traditional diagnostic tests
  • Present current data regarding outpatient care of cardiac patients

Financial Disclosure:

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Jonathan Abrams, MD serves on the speaker’s bureau for Merck, Pfizer, and Parke-Davis. John P. DiMarco, MD, PhD is a consultant for Novartis and does research for Medtronic and Guidant. Michael H. Crawford, MD is on the speaker's bureau for Pfizer.

Copyright 2005 AHC Media. All rights reserved.